MedTrace Logo

Extended Spectrum Betalactamase Producing Bacteria; Epidemiology and Treatment in Non-hospitalized Patients

NCT01838213 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 760

Last updated 2015-11-23

Study results available
· View outcomes & findings →

Summary

This project aims at investigating the duration of human fecal carriage of bacteria harboring plasmid-borne resistance genes expressing Extended Spectrum beta-lactamases (ESBL), risk factors for infections with such bacteria and persistence, mobility and spread of ESBL in the environment and within households. It also aims to compare different methods of detecting ESBL carriage and treat patients with urinary tract infection caused by these bacteria.

Conditions

Sponsors & Collaborators

  • Helse Sor-Ost

    collaborator OTHER_GOV

  • University Hospital of North Norway

    collaborator OTHER

  • University of Oslo

    collaborator OTHER

  • Vestre Viken Hospital Trust

    lead OTHER

Principal Investigators

  • Pål A Jenum, PhD · Vestre Viken Hospital Trust

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-02-28
Primary Completion
2014-12-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01838213 on ClinicalTrials.gov